Stable Ischemic Heart Disease
Authors: Jennifer Fisher Wilson
Journal: Annals of Internal Medicine (2014)

In the Clinic7 January 2014Stable Ischemic Heart DiseaseJennifer Fisher Wilson, Deborah Cotton, MD, MP, Darren Taichman, MD, PhD, and Sankey Williams, MDJennifer Fisher Wilson, Deborah Cotton, MD, MP, Darren Taichman, MD, PhD, and Sankey Williams, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-160-1-201401070-01001 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Stable ischemic heart disease (SIHD) affects many millions of Americans, with associated annual costs measured in tens of billions of dollars. It is a leading cause of death in the United States. SIHD occurs when coronary artery disease (CAD) reduces the blood supply to the heart and typically causes recurrent chest pain or pressure known as angina. The angina is exacerbated by activity or stress, lasts for minutes not seconds or hours, and goes away with rest or medication. Timely diagnosis and optimal treatment can reduce complications and mortality from SIHD.Recent clinical guidelines are designed to improve clinical care ...References1. Fihn SD, Gardin JM, Abrams J, et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354-e471. Google Scholar2. Qaseem A, Fihn SD, Williams S, Dallas P, Owens DK, Shekelle P, for the Clinical Guidelines Committee of the American College of Physicians. Diagnosis of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/ American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med. 2012;157:729-34. Google Scholar3. Qaseem A, Fihn SD, Williams S, Dallas P, Owens DK, Shekelle P, for the Clinical Guidelines Committee of the American College of Physicians. Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/ American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med. 2012;157:735-43. Google Scholar4. Anderson JL, Adams CD, Antman EM, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e663-828. Google Scholar5. Kumar A, Cannon CP. Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc. 2009;84:917-38. Google Scholar6. Pryor DB, Shaw L, Harrell FE Jr, et al. Estimating the likelihood of severe coronary artery disease. Am J Med. 1991;90:553-62. Google Scholar7. Hachamovitch R, Berman DS, Kiat H, et al. Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia. Am J Cardiol. 1997;80:426-33. Google Scholar8. Mark DB, Hlatky MA, Harrell FE Jr, et al. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med. 1987;106:793-800. Google Scholar9. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388-98. Google Scholar10. Reducing the health consequences of smoking: 25 years of progress: a report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, CDC, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1989. DHHS publication no. (CDC) 89-8411. Google Scholar11. Kottke TE, Battista RN, DeFriese GH, Brekke ML. Attributes of successful smoking cessation interventions in medical practice. A meta-analysis of 39 controlled trials. JAMA. 1988;259:2883-9. Google Scholar12. Taylor CB, Houston-Miller N, Killen JD, DeBusk RF. Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. Ann Intern Med. 1990;113:118-23. Google Scholar13. Goldberg AC, Ostlund RE, Jr., Bateman JH, et al. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol. 2006;97:376-9. Google Scholar14. Hallikainen MA, Sarkkinen ES, Uusitupa MI. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J Nutr. 2000;130:767-76. Google Scholar15. Nguyen TT, Dale LC, von BK, et al. Cholesterol-lowering effect of stanol ester in a US population of mildly hypercholesterolemic men and women: a randomized controlled trial. Mayo Clin Proc. 1999;74:1198-206. Google Scholar16. Chen JT, Wesley R, Shamburek RD, et al. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy. 2005;25:171-83. Google Scholar17. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Circulation. 2013 Nov 12. [Epub ahead of print] Google Scholar18. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. Google Scholar19. Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD, editor. Textbook of Hypertension. Blackwell Scientific Publications, 1994. Google Scholar20. Rees K, Bennett P, West R, et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev. 2004;CD002902. Google Scholar21. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. Google Scholar22. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81-106. Google Scholar23. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150:405-10. Google Scholar24. de Diego C, Vila-Corcoles A, Ochoa O, et al. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J. 2008;30:209-16. Google Scholar25. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429-35. Google Scholar26. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302. Google Scholar27. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-8. Google Scholar28. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. Google Scholar29. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951-8. Google Scholar30. Tepper D. Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Congest Heart Fail. 1999;5:184-5. Google Scholar31. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334: 1349-55. 761. Google Scholar32. Leizorovicz A, Lechat P, Cucherat M, et al. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J. 2002;143:301-7. Google Scholar33. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-92. Google Scholar34. Fortmann SP, Burda BU, Senger CA, et al. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;159:824-34. Google Scholar35. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283-91. Google Scholar36. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analydsis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281:1927-36. Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95:311- 6. Google Scholar37. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-16. Google Scholar38. Farkouh ME, Domanski M, Sleeper LA, et al; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375-84. N Engl J Med. 2012; 367:2375-84. Google Scholar39. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991-1001. Google Scholar40. Gibbons RJ, Abrams J, Chatterjee K, et al; American College of Cardiology. ACC/AHA 2002 guideline update for the management of patients with chronic stable anginasummary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159-68. Google Scholar41. Braunwald E, Mark D, Jones RH. Unstable angina: diagnosis and management. Clinical Practice Guideline Number 10. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services; 1994. Google Scholar42. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med. 1979;300: 1350-8. Google Scholar Author, Article, and Disclosure InformationAffiliations: CME Objective: To review current evidence for diagnosis, treatment, and practice improvement of stable ischemic heart disease.Funding Source: American College of Physicians.Disclosures: Ms. Wilson, ACP Contributing Author, has disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-2656.Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that she has no financial relationships or interests to disclose. Darren B. Taichman, MD, PhD, Executive Deputy Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer.With the assistance of additional physician writers, Annals of Internal Medicine editors develop In the Clinic using resources of the American College of Physicians, including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byManagement of Acute and Late Endocrine Effects Following Childhood Cancer TreatmentSynthesis and characterization of a novel organic nitrate NDHP: Role of xanthine oxidoreductase-mediated nitric oxide formationExperiences with the survivorship care plan in primary care providers of childhood cancer survivors: a mixed methods approachPredictors of attendance at specialized survivor clinics in a population-based cohort of adult survivors of childhood cancerEngagement and experience with cancer-related follow-up care among young adult survivors of childhood cancer after transfer to adult careFacilitating the Transition from Pediatric-Oriented to Adult-Oriented Primary CareA Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic MalignanciesBone mineral density after childhood cancer in 346 long-term adult survivors of childhood cancer 7 January 2014Volume 160, Issue 1Page: ITC1-1KeywordsAnginaAngiographyCardiovascular therapyExerciseIschemiaMedical risk factorsMortalityPercutaneous coronary interventionRevascularizationStenosis ePublished: 7 January 2014 Issue Published: 7 January 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...